ArticleMolecular and cellular biochemistry2026
Single-cell transcriptomics reveals glycolytic heterogeneity and identifies STC2 as a key regulator of metabolic reprogramming in osteosarcoma.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Osteosarcoma (OS) exhibits profound metabolic reprogramming, yet the specific cellular subpopulations and regulatory networks governing glycolysis within the tumor microenvironment remain elusive. We integrated single-cell RNA sequencing (scRNA-seq) data from 12 OS samples with bulk transcriptomics and high-dimensional Weighted Gene Co-expression Network Analysis (hdWGCNA). The identified core metabolic regulator was comprehensively validated in vitro using functional assays and Seahorse extracellular flux analysis in MG-63 and U2OS cells. Our single-cell analysis revealed marked metabolic heterogeneity, identifying a dedifferentiated "Chondroblastic" subpopulation characterized by high glycolytic flux and stem-like features. Multi-omics screening pinpointed Stanniocalcin-2 (STC2) as a core prognostic regulator of this phenotype. In vitro validation demonstrated that STC2 knockdown significantly suppressed OS cell proliferation, invasion, and the expression of key glycolytic enzymes (PGK1, LDHA, and GLUT1). Crucially, extracellular flux analysis revealed that STC2 depletion induced a profound metabolic shift, substantially attenuating glycolysis (decreased ECAR) while concomitantly enhancing mitochondrial oxidative phosphorylation (increased OCR). We present a high-resolution single-cell metabolic map of OS, identifying STC2 as a critical regulator of glycolysis-associated tumor progression. Targeting STC2 effectively reverses metabolic reprogramming-shifting energy metabolism from glycolysis toward oxidative phosphorylation-offering a promising therapeutic strategy for osteosarcoma.
Indexed as
Identifiers
42166004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.